VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
LY007
Phase 1
Small molecule
S
Shanghai Longyao Biotechnology Inc., Ltd.
1
Indications
2
Total Trials
2
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
R/R B-NHL
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
R/R B-NHL
Phase 1
Recruiting
Clinical
Trials by Indication
[1]
R/R B-NHL
2 trials
An Evaluation of LY007 Cell Injection for r/r B-NHL
Recruiting
·
S
Shanghai Longyao Biotechnology Inc., Ltd.
·
Phase 1
·
NCT06279611
·
18 enrolled
An Evaluation of LY007 Cell Injection for r/r B-NHL
Recruiting
·
R
Ruijin Hospital
·
Phase 1
·
NCT06364852
·
18 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for LY007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
LY007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for LY007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Shanghai Longyao Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
S
Shanghai Longyao Biotechnology Inc., Ltd.
Related News